BridgeMD
New treatment option for SCI - Spinal Cord Injury
Official title Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury
ClinicalTrials.gov ID: NCT07106060
What this study is testing
- What it's testing
- The primary objective of this clinical trial is to investigate the efficacy of motor imagery-based brain-computer interface (MI-BCI) technology in improving motor function among patients with spinal cord injury (SCI), as well as its impact on cortical motor area function across varying states. To achieve this, the study will implement MI-BCI intervention in SCI patients, evaluate post-treatment motor function improvements, and assess changes in cortical motor area oxygen metabolism (via functional near-infrared spectroscopy, fNIRS) and neural activity (via electroencephalography, EEG).
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- The vital signs are stable and the spine is stable, making the subject suitable for exercise testing.
- Patients with spinal cord injury (SCI) who meet the international diagnostic criteria for SCI neurology revised by the American SCI Society in 2019...
- The injury level of SCI is C5-T12, and the ASIA grade is A-C.
- The course of the disease is ≤12 months (but the spinal shock period must have passed).
- Age: 18-75 years old, regardless of gender.
You likely can't join if
- Those with tumors, tuberculosis, hematologic diseases, or dysfunction of important organs such as the heart and liver;
- Those with unstable fractures;
- Those with severe abnormal limb muscle tone and joint contracture deformities;
- Those with severe pain that cannot tolerate activities;
- Those with severe emotional problems who cannot cooperate to complete the study.
See the full eligibility criteria
- The vital signs are stable and the spine is stable, making the subject suitable for exercise testing.
- Patients with spinal cord injury (SCI) who meet the international diagnostic criteria for SCI neurology revised by the American SCI Society in 2019 and have been diagnosed by CT or MRI.
- The injury level of SCI is C5-T12, and the ASIA grade is A-C.
- The course of the disease is ≤12 months (but the spinal shock period must have passed).
- Age: 18-75 years old, regardless of gender.
- Good cognitive function, able to understand and actively participate in the training program, and willing to sign the informed consent form for this clinical study.
- Those with tumors, tuberculosis, hematologic diseases, or dysfunction of important organs such as the heart and liver;
- Those with unstable fractures;
- Those with severe abnormal limb muscle tone and joint contracture deformities;
- Those with severe pain that cannot tolerate activities;
- Those with severe emotional problems who cannot cooperate to complete the study.
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.